Jan 31, 2022 • 10:00am - 12:00pm EST
Ocuphire will host a Virtual Investor R&D Day at which six ophthalmic Key Opinion Leaders (KOLs) from retina, optometry and refractive surgery practices will share their thoughts on three large unmet indications, RM, presbyopia, and DR/DME, addressed by Ocuphire’s two late-stage clinical drug assets, Nyxol and APX3330, and provide status updates on their development programs.
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.
Ocuphire Pharma, Inc.
37000 Grand River Ave., Suite 120
Farmington Hills, MI 48335
250 West 55th Street, Suite 3401
New York, NY 10019
American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, NY 11219